Abstract:IMPORTANCE This study demonstrates that tislelizumab in combination with chemotherapy is associated with improved progression-free survival (PFS) in patients with advanced squamous non-small-cell lung cancer (sq-NSCLC). OBJECTIVE To assess the efficacy and safety/tolerability of tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for patients with advanced sq-NSCLC. DESIGN, SETTING, AND PARTICIPANTS This open-label, randomized phase 3 clinical trial was conducted at 46 sites in China between July 2018 and June 2019 and included patients with treatment-naive, histologically confirmed stage IIIB/IV sq-NSCLC. The data cutoff for these analyses was December 6, 2019; data extraction occurred on January 7, 2020. INTERVENTIONS Patients were randomized (1:1:1) to receive 1 of the following regimens intravenously on a 21-day cycle: tislelizumab (200 mg, day 1) plus paclitaxel (175 mg/m(2), day 1) and carboplatin (area under the concentration of 5, day 1) (arm A); tislelizumab plus nab-paclitaxel (100 mg/m(2), days 1, 8, and 15) and carboplatin (arm B); and paclitaxel and carboplatin (arm C). Patients were stratified by disease stage and tumor programmed cell death 1 ligand 1 (PD-L1) expression (<1% vs 1%-49% vs >= 50%). MAIN OUTCOMES AND MEASURES The primary end point was progression-free survival (PFS) assessed by an independent review committee (IRC). Secondary end points included overall survival, investigator-assessed (INV) PFS, IRC-assessed objective response rate (ORR), and IRC-assessed duration of response, as well as the incidence and severity of adverse events (AEs). RESULTS Overall, 355 patients (median [range] age, 62 [34-74] years; 330 men [91.7%]) with sq-NSCLC received treatment. After a median study follow-up of 8.6 months (95% CI, 8.1-9.0 months), IRC-assessed PFS was significantly improved with tislelizumab plus chemotherapy (arm A, 7.6 months; arm B, 7.6 months) vs chemotherapy alone (arm C, 5.5 months; hazard ratios were 0.524 (95% CI, 0.370-0.742; P < .001 [A vs C]) and 0.478 (95% CI, 0.336-0.679; P < .001 [B vs C]). Higher IRC-assessed ORR and longer IRC-assessed duration of response were observed in arms A (72.5%; 8.2 months) and B (74.8%; 8.6 months) vs C (49.6%; 4.2 months). No association was observed between PD-L1 expression and IRC-assessed PFS or ORR. Discontinuation of any treatment because of AEs was reported in 15 (12.5%; arm A), 35 (29.7%; arm B), and 18 (15.4%; arm C) patients. In each arm, the most common grade of 3 or greater AE was decreased neutrophil levels, which aligned with known chemotherapy toxic effects. Six treatment-related AEs leading to death occurred; however, no deaths were solely attributed to tislelizumab. CONCLUSIONS AND RELEVANCE In this phase 3 randomized clinical trial, adding tislelizumab to chemotherapy was associated with significantly prolonged IRC-assessed PFS, higher IRC-assessed ORRs, and a manageable safety/tolerability profile in patients with advanced sq-NSCLC, regardless of PD-L1 expression.

THERAPEUTIC EFFECT OF OXALIPLATIN COMBINED WITH THYMOSIN ON LUNG CANCER AND ITS INFLUENCE ON SERUM T LYMPHOCYTE, INFLAMMATORY FACTOR, AND TUMOUR NECROSIS FACTOR

Short-term effect of combined therapy with Jinlong Capsule (金龙胶囊) and transcatheter arterial chemoembolization on patients with primary hepatic carcinoma and its influence on serum osteopontin expression

Intratumoral injection of lipiodol pingyangmycin combined with thalidomide in treatment of recurrent advanced liver cancer

Short-Term Effect Of Combined Therapy With Jinlong Capsule ((Sic)) And Transcatheter Arterial Chemoembolization On Patients With Primary Hepatic Carcinoma And Its Influence On Serum Osteopontin Expression

Short-term efficacy of oxaliplatin as interventional therapy for liver cancer, and its effect on serum CD163 and AFU

Effect of Thymosin on Inflammatory Factor Levels, Immune Function, and Quality of Life in Lung Cancer Patients Undergoing Radical Thoracoscopic Surgery

Clinical Study of Thymosin α1 Combined with Pemetrexed in the Treatment of Elderly Patients with Advanced Lung Adenocarcinoma

A preliminary analysis of integrating thymosin α1 into concurrent chemoradiotherapy and consolidative immunotherapy.

OX40 and OX40L Protein Expression of Tumor Infiltrating Lymphocytes in Non-Small Cell Lung Cancer and Its Role in Clinical Outcome and Relationships with Other Immune Biomarkers

Sesquiterpene Lactone Parthenolide Markedly Enhances Sensitivity of Human A549 Cells to Low-Dose Oxaliplatin Via Inhibition of NF-κB Activation and Induction of Apoptosis

Effect of Human Hydrosalpinx Fluid on in Vitro Mouse Embryogenesis.

The effect of the levels of serum、EBC ET-1 and serum T lymphocyte subtypes in lung cancer treatment with thymo-penti n and chemotherapy

Thymosin α1 combined with XELOX improves immune function and reduces serum tumor markers in colorectal cancer patients after radical surgery

Clinical efficacy of thymosin alpha 1 combined with multi-modality chemotherapy and its effects on immune function of patients with pulmonary tuberculosis complicated with diabetes

Oxaliplatin facilitates tumor-infiltration of T cells and natural-killer cells for enhanced tumor immunotherapy in lung cancer model

Clinical and Experimental Study of Oxaliplatin in Treating Human Gastric Carcinoma

Efficacy and Safety Assessment of Intrathoracic Perfusion Chemotherapy Combined with immunological factor Interleukin-2 in the Treatment of Advanced Non-Small Cell Lung Cancer: A Retrospective Cohort Study

Curative effect of endostar combined with oxaliplatin in the treatment of primary hepatic carcinoma and its influence on immune cells.

Clinical Analysis of Curative Effect on Oxaliplatin As Adjuvant Chemotherapy for Postoperative Hepatocellular Carcinoma

Therapeutic Efficacy of Oxaliplatin and Pembrolizumab Combination Treatment for Triple-Negative Breast Cancer

Impact of thymosin 1 as an immunomodulatory therapy on long-term survival of non-small cell lung cancer patients after R0 resection: a propensity score-matched analysis